APTO - アポト―ス・バイオサイエンシズ （Aptose Biosciences Inc.）

SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in the Oppenheimer 33 rd Annual Healthcare Conference being held March 13-15, 2023, in a virtual format.

MIGI has seen its SMA50 which is now 65.60%. In looking the SMA 200 we see that the stock has seen a -43.82%. APTO has seen its SMA50 which is … The post Morning Worth Watching Stock: Mawson Infrastructure Group, Inc. (NASDAQ:MIGI 4.47%), Aptose Biosciences Inc. (NASDAQ:APTO -0.83%) appeared first on Stocks Equity .

In Monday’s session, Aptose Biosciences Inc. (NASDAQ:APTO) marked $0.74 per share, down from $0.76 in the previous session. While Aptose Biosciences Inc. has underperformed by -2.51%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, APTO fell by -34.43%, with highs and lows ranging from $1.55 to […]

APTO has seen its SMA50 which is now 14.95%. In looking the SMA 200 we see that the stock has seen a -5.36%. RNAZ has seen its SMA50 which is … The post Eye-popping stocks: Aptose Biosciences Inc. (NASDAQ:APTO -3.68%), TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ 1.96%) appeared first on Stocks Equity .

During the last session, Aptose Biosciences Inc. (NASDAQ:APTO)’s traded shares were 0.38 million, with the beta value of the company hitting 1.54. At the end of the trading day, the stock’s price was $0.58, reflecting an intraday gain of 7.61% or $0.04. The 52-week high for the APTO share is $1.55, that puts it down … Aptose Biosciences Inc. (NASDAQ: APTO): Can A Stock That’s Down -57.04% YTD Still Be Considered In Loss Territory? Read More »

The following slide deck was published by Aptose Biosciences Inc.

During the same quarter in the previous year, the business earned ($0.18) earnings per share. Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald decreased … Read Full Story at source (may require registration) The post Oppenheimer Equities Analysts Raise Earnings Estimates for Aptose Biosciences Inc. (NASDAQ:APTO) appeared first on ForexTV .

Aptose Biosciences Inc. (NASDAQ: APTO ) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. HM43239 is being investigated in an ongoing international Phase 1/2 … Full story available on Benzinga.com

Aptose Biosciences (APTO) is scheduled to announce Q4 earnings results on Tuesday, March 22nd, after market close.The consensus EPS Estimate is -$0.17Over the last 3 months, EPS…

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO , TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer''s 32 nd Annual Healthcare Conference: Aptose Presentation - Oppenheimer''s 32nd Annual Healthcare Conference Date: Tuesday, March 15, 2022 Time: 10:00 … Full story available on Benzinga.com

Aptose Biosciences Inc. (NASDAQ: APTO ) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. HM43239 is being investigated in an ongoing international Phase 1/2 … Full story available on Benzinga.com

Aptose Biosciences (APTO) is scheduled to announce Q4 earnings results on Tuesday, March 22nd, after market close.The consensus EPS Estimate is -$0.17Over the last 3 months, EPS…

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO , TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer''s 32 nd Annual Healthcare Conference: Aptose Presentation - Oppenheimer''s 32nd Annual Healthcare Conference Date: Tuesday, March 15, 2022 Time: 10:00 … Full story available on Benzinga.com

Aptose Biosciences Inc (APTO) shares closed today 12.6% higher than it did at the end of yesterday. The stock is currently up 12.6% year-to-date, down 65.3% over the past 12 months, and up 12.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.55 and as low as $1.30 this week.Shares closed 78.9% below its 52-week high and 40.7% above its 52-week low.Trading volume this week was 3.6% higher than the 10-day average and 56.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 115.4% The company's stock price performance over the past 12 months lags the peer average by -4010.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.